2020
Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond
Freedman RA, Sedrak MS, Bellon JR, Block CC, Lin NU, King TA, Minami C, VanderWalde N, Jolly TA, Muss HB, Winer EP. Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. Journal Of The National Cancer Institute 2020, 113: 355-359. PMID: 32449757, PMCID: PMC7313961, DOI: 10.1093/jnci/djaa079.Peer-Reviewed Original ResearchConceptsOlder patientsBreast cancerSevere acute respiratory syndrome coronavirus 2 exposureTreatment-related toxicityMultidisciplinary treatment approachBreast cancer patientsUnique clinical considerationsCOVID-19Chemotherapy toxicityMetastatic diseaseTreatment delayCancer patientsFunctional statusCare considerationsTreatment decisionsFunctional declineTherapeutic benefitTreatment prioritiesClinical considerationsTreatment approachesPatientsOlder adultsCOVID-19 pandemicCancerToxicityReversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
Waks AG, Cohen O, Kochupurakkal B, Kim D, Dunn CE, Buendia J, Wander S, Helvie K, Lloyd MR, Marini L, Hughes ME, Freeman SS, Ivy SP, Geradts J, Isakoff S, LoRusso P, Adalsteinsson VA, Tolaney SM, Matulonis U, Krop IE, D’Andrea A, Winer EP, Lin NU, Shapiro GI, Wagle N. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Annals Of Oncology 2020, 31: 590-598. PMID: 32245699, PMCID: PMC7946408, DOI: 10.1016/j.annonc.2020.02.008.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerPlatinum chemotherapyDNA-damaging therapyMechanisms of resistanceBreast cancerMetastatic breast cancer patientsBreast cancer patientsTumor DNA sequencingNovel sequence alterationsWhole-exome sequencingDNA-damaging therapiesTreatment failureCancer patientsFunctional statusDisease progressionTumor biopsiesClinical cohortImmunohistochemical stainingSubsequent linesBRCA1/2 mutationsTherapeutic benefitPatientsUseful biomarkerFunctional assessmentTumor sections
2008
NCCN Task Force Report: breast cancer in the older woman.
Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. Journal Of The National Comprehensive Cancer Network 2008, 6 Suppl 4: s1-25; quiz s26-7. PMID: 18597715, DOI: 10.6004/jnccn.2008.2004.Peer-Reviewed Original ResearchConceptsBreast cancerOlder patientsOlder womenBreast cancer treatment recommendationsCancer treatment recommendationsSurgical axillary stagingGeriatric assessment toolsPresence of comorbiditiesMetastatic breast cancerBreast cancer patientsRandomized clinical trialsCurative surgeryNCCN institutionsAxillary stagingEndocrine therapyGeriatric oncologySupportive therapyTask ForceMedical oncologyCancer patientsFunctional statusOncology settingTreatment recommendationsClinical trialsMultidisciplinary panel
1997
Breast Cancer
Chu L, Winer E. Breast Cancer. 1997, 257-279. DOI: 10.1007/978-1-4757-2705-0_20.Peer-Reviewed Original ResearchBreast cancerOlder womenMost randomized studiesBreast cancer increasesWomen 65 yearsTreatment of patientsYears of ageOlder patientsRandomized studyIndolent diseaseCancer increasesFunctional statusGeriatric populationRelative survivalTumor biologyAge groupsCancerFemale populationYoung womenCommon diseaseWomenPatientsAgeDiseaseSocial support